View Financial HealthNautilus Biotechnology 配当と自社株買い配当金 基準チェック /06Nautilus Biotechnology配当金を支払った記録がありません。主要情報n/a配当利回り-0.4%バイバック利回り総株主利回り-0.4%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 30Nautilus Biotechnology, Inc., Annual General Meeting, Jun 17, 2026Nautilus Biotechnology, Inc., Annual General Meeting, Jun 17, 2026.お知らせ • Apr 10Nautilus Biotechnology, Inc. to Report Q1, 2026 Results on Apr 28, 2026Nautilus Biotechnology, Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 28, 2026New Risk • Apr 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$83m net loss in 3 years).新しいナラティブ • Mar 05Proteomics Demand And Early Access Services Will Support A Stronger Long Term OpportunityCatalysts About Nautilus Biotechnology Nautilus Biotechnology is developing a proteomics platform built around its Voyager instrument and Iterative Mapping technology to measure proteins and proteoforms at single molecule resolution for research and drug discovery customers. What are the underlying business or industry changes driving this perspective?お知らせ • Feb 25Nautilus Biotechnology, Inc. Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, At US HUPO 2026Nautilus Biotechnology, Inc. debuted the Voyager Platform, which is designed to power the Iterative Mapping of up to 10 billion intact proteins and proteoforms simultaneously in a single run. The Voyager Platform was unveiled during the US HUPO 2026 conference in St. Louis, highlighting its ability to identify and quantify intact protein molecules with machine-learning powered analysis - all on an integrated platform with a user-friendly touchscreen interface and benchtop design that requires no special lab facility requirements. The Voyager Platform is the result of Nautilus' unique cross-disciplinary approach to protein analysis, combining integrated reagents, fluidics, imaging, ultra-dense nano-array flow cells, and machine learning-powered algorithms, to enable Iterative Mapping and deliver on the full potential of proteomics. The company launched its Iterative Mapping Early Access Program in January 2026 to provide scientists with an initial opportunity to use Nautilus' novel single-molecule proteomic analysis method and platform ahead of commercial availability. The program is currently accepting project proposals and is offered first as a fee-for-service through Nautilus Proteomics Analysis Services, followed by a limited number of Voyager instrument placements in advance of full commercial launch expected in late 2026. The program's initial offering is the Nautilus Tau Proteoforms assay, which enables quantification of up to 768 full-length tau proteoform groups that are not accessible with standard proteomics methods. Results from Nautilus' ongoing collaboration with the Buck Institute have established the instrument's qualification and readiness for broader research applications. Joint research results between Nautilus and the Buck Institute have provided insights into novel tau biology and are now being presented at scientific conferences. In addition to the platform showcase, Nautilus will present data across multiple sessions at US HUPO, including an oral presentation on advancing proteomics through Iterative Mapping, posters detailing tau proteoform analysis in Alzheimer's disease and large-scale proteoform detection capabilities, and a sponsored lunch seminars. On February 24, February 24, 2026, Nautilus' Vice President of Scientific Engagement, Sheri Wilcox, Ph.D., and Birgit Schilling, Ph.D., Associate Professor and Director of the Mass Spectrometry Core at the Buck Institute for Research on Aging, will showcase how Iterative Mapping is transforming proteomics and enabling new insights into the role of tau biology in neurodegeneration and aging.お知らせ • Feb 05Nautilus Biotechnology, Inc. to Report Q4, 2025 Results on Feb 26, 2026Nautilus Biotechnology, Inc. announced that they will report Q4, 2025 results Pre-Market on Feb 26, 2026お知らせ • Jan 08Nautilus Biotechnology, Inc. Announces the Launch of an Early Access ProgramNautilus Biotechnology, Inc. announced the launch of an Early Access Program for its novel proteomics platform, with a tau proteoforms assay as its first offering. The program makes Nautilus' Iterative Mapping approach to measuring proteins and their variants available to an exclusive group of researchers. Nautilus' IterativeMapping method enables single-molecule analysis of proteins and proteoforms and is designed to achieve comprehensive proteome coverage and detail at scale. The method empowers researchers to precisely map combinatorial patterns of post-translational modifications on individual proteins and study how those patterns evolve over the course of diseases such as Alzheimer's and other neurodegenerative disorders. Participants will receive support from Nautilus for guidance on data interpretation, quantification, and analysis, supporting rapid adoption and the generation of actionable biological insights. The tau proteoforms assay demonstrates the strong performance and accessibility of the Nautilus Platform. A Nautilus preprint debuting the assay details the platform's capabilities in analyzing Alzheimer's disease brain samples, providing initial validation of its accuracy, sensitivity, dynamic range, and reproducibility for interacting billions of single-protein molecules at scale. Successful adoption by first-time users at the Buck Institute reinforces the platform's accessibility and commercial readiness for research use. In addition to standard tau assays for Alzheimer's and neurodegenerative research, the Early Access Program offers exclusive development partnerships to support the creation of custom assays tailored to specific research applications.お知らせ • Nov 05Nautilus Biotechnology Reports Successful Installation and Testing of Its First Field Evaluation Unit At the Buck Institute for Research on AgingNautilus Biotechnology, Inc. and the Buck Institute for Research on Aging announced the successful installation and testing of Nautilus' first external field evaluation unit. Using the instrument for more than 6 months, researchers generated highly reproducible data from neurodegenerative disease samples prepared and acquired at the Buck Institute in the San Francisco Bay Area, CA. The operation of Nautilus' first instrument deployed at an external site marks a critical milestone in providing independent research labs with direct access to the company's single-molecule proteomics platform, as well as in its acceleration of broader research and development efforts to investigate severe conditions such as Alzheimer's disease. Birgit Schilling and Lisa Ellerby, were the first to install, pilot, and utilize the Nautilus platform on their grounds - it is a testament to rigorous approach to conducting and bringing high-caliber science into labs everywhere. The unit employs Nautilus' Iterative Mapping approach and proprietary tau proteoform assay developed to quantify 7768 proteoform groups, enabling the Buck Institute to apply to their samples high-resolution analysis of the protein modifications that most strongly influence disease progression. Their joint efforts demonstrated that the tau assay generates highly reproducible end-to-end platform data across sites and users and established the instrument's qualification and readiness for broader research applications.お知らせ • Oct 07Nautilus Biotechnology, Inc. to Report Q3, 2025 Results on Oct 28, 2025Nautilus Biotechnology, Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Oct 28, 2025Recent Insider Transactions • Sep 11Co-Founder recently bought US$136k worth of stockOn the 8th of September, Sujal Patel bought around 200k shares on-market at roughly US$0.68 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Sujal has been a buyer over the last 12 months, purchasing a net total of US$159k worth in shares.Price Target Changed • Jul 29Price target increased by 33% to US$2.50Up from US$1.88, the current price target is provided by 1 analyst. New target price is 235% above last closing price of US$0.75. Stock is down 72% over the past year. The company is forecast to post a net loss per share of US$0.60 next year compared to a net loss per share of US$0.56 last year.お知らせ • Jul 15Nautilus Biotechnology, Inc. to Report Q2, 2025 Results on Jul 31, 2025Nautilus Biotechnology, Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 31, 2025Price Target Changed • Jun 04Price target increased by 16% to US$2.17Up from US$1.88, the current price target is an average from 3 analysts. New target price is 180% above last closing price of US$0.77. Stock is down 70% over the past year. The company is forecast to post a net loss per share of US$0.59 next year compared to a net loss per share of US$0.56 last year.お知らせ • May 03Nautilus Biotechnology Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketOn May 1st, 2025, Nautilus Biotechnology, Inc. received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between March 19, 2025, through April 30, 2025, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until October 28, 2025 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). The letter has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on Nasdaq, subject to the Company’s compliance with the other listing requirements of Nasdaq. In order to regain compliance with Nasdaq’s minimum bid price requirement, shares of the Company’s common stock must maintain a closing bid price of at least $1.00 for a minimum of ten consecutive business days during the Compliance Period, unless the Staff exercises its discretion to extend this ten day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). In the event the Company does not regain compliance by the end of the Compliance Period, the Company may be eligible for an additional 180 calendar days to regain compliance (the “Second Compliance Period”) pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(i) by transferring to the Nasdaq Capital Market. To qualify for the Second Compliance Period, the Company would need to submit a transfer application and pay an application fee. In addition, the Company would be required to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for Nasdaq, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the Second Compliance Period by effecting a reverse stock split, if necessary. However, if it appears to Nasdaq that the Company will be unable to cure the deficiency, or if the Company is not otherwise eligible for the additional cure period, Nasdaq will provide notice that the Company’s shares of common stock will be subject to delisting. There can be no assurance that the Company will be eligible for the Second Compliance Period, if applicable, or that the Staff would grant the Company’s request for continued listing subsequent to any delisting notification. The Company intends to actively monitor the closing bid price of its shares of common stock during the Compliance Period and may, if appropriate, evaluate available options to resolve the deficiency and regain compliance with the minimum bid price requirement. While the Company is exercising diligent efforts to maintain the listing of its common stock on the Nasdaq Global Select Market, there can be no assurance that the Company will be able to regain or maintain compliance with the minimum bid price requirement or any other Nasdaq listing standard.お知らせ • May 01Nautilus Biotechnology, Inc., Annual General Meeting, Jun 20, 2025Nautilus Biotechnology, Inc., Annual General Meeting, Jun 20, 2025.Price Target Changed • Apr 29Price target increased by 16% to US$2.17Up from US$1.88, the current price target is an average from 3 analysts. New target price is 195% above last closing price of US$0.73. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$0.65 next year compared to a net loss per share of US$0.56 last year.お知らせ • Apr 16Nautilus Biotechnology, Inc. to Report Q1, 2025 Results on Apr 29, 2025Nautilus Biotechnology, Inc. announced that they will report Q1, 2025 results Pre-Market on Apr 29, 2025New Risk • Apr 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$94.7m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 8.2% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$99m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$94.7m market cap).Seeking Alpha • Feb 28Nautilus: Trading Below An Albeit Lower Net Cash FigureSummary Nautilus Biotechnology, Inc. faces reflexivity risks and macroeconomic challenges, but its commercial plan starts next year with substantial cash reserves. Trading below cash value, Nautilus' patents and bio-informatics platform are not being given too much credit by markets. Although, they seem to expect that company to be minimally viable once they have an additional $30 million of cash, which still may not be enough depending on commercial costs. The company aims for commercialization by late 2026, with anticipated ASPs above $1 million, but that doesn't sound like it will be enough, and we'll need to see commercial outcomes. NAUT stock is probably still going to be subject to reflexivity risks for a while, so we stay on the sidelines while costs of capital remain stubbornly higher. Read the full article on Seeking AlphaNew Risk • Feb 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 7.7% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$99m net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change).Price Target Changed • Feb 28Price target increased by 12% to US$4.00Up from US$3.56, the current price target is an average from 3 analysts. New target price is 208% above last closing price of US$1.30. Stock is down 52% over the past year. The company is forecast to post a net loss per share of US$0.67 next year compared to a net loss per share of US$0.56 last year.お知らせ • Feb 06Nautilus Biotechnology, Inc. to Report Q4, 2024 Results on Feb 27, 2025Nautilus Biotechnology, Inc. announced that they will report Q4, 2024 results Pre-Market on Feb 27, 2025New Risk • Dec 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 11% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$107m net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change).Price Target Changed • Oct 30Price target decreased by 14% to US$3.56Down from US$4.13, the current price target is an average from 4 analysts. New target price is 34% above last closing price of US$2.65. Stock is up 3.5% over the past year. The company is forecast to post a net loss per share of US$0.64 next year compared to a net loss per share of US$0.51 last year.お知らせ • Oct 08Nautilus Biotechnology, Inc. to Report Q3, 2024 Results on Oct 29, 2024Nautilus Biotechnology, Inc. announced that they will report Q3, 2024 results Pre-Market on Oct 29, 2024Recent Insider Transactions Derivative • Sep 19Senior Vice President of Operations notifies of intention to sell stockMary Godwin intends to sell 35k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of September. If the sale is conducted around the recent share price of US$2.85, it would amount to US$100k. As of today, Mary currently holds no shares directly (This sale likely refers to shares that have not yet been received). Company insiders have collectively bought US$57k more than they sold, via options and on-market transactions, in the last 12 months.お知らせ • Sep 17Nautilus Biotechnology, Inc. Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing OfficerNautilus Biotechnology, Inc. announced the appointment of Kentaro (Ken) Suzuki as Chief Marketing Officer. Mr. Suzuki joins Nautilus after 25 years in product and marketing leadership roles at Agilent Technologies, most recently serving as Vice President and General Manager of Agilent’s Mass Spectrometry division. He has held numerous leadership positions at Agilent, including in the Strategic Program Office and Certified Pre-Owned Instruments, CrossLab Services and Support, and Spectroscopy. Mr. Suzuki’s track record in the life sciences and technology sector spans nearly three decades of innovation across marketing, product, finance, and research and development. Previously, he held roles in application and sales at Takeda Pharmaceuticals in Tokyo, Japan, and in finance at Hewlett-Packard (HP) before contributing to the founding of Agilent. Mr. Suzuki received his M.B.A. from the Haas School of Business at the University of California, Berkeley, and his B.S. in Biological Engineering from Cornell University. He will be based in Nautilus’ research and development headquarters in the San Francisco Bay Area.分析記事 • Jul 27We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...お知らせ • Jul 10Nautilus Biotechnology, Inc. to Report Q2, 2024 Results on Jul 30, 2024Nautilus Biotechnology, Inc. announced that they will report Q2, 2024 results Pre-Market on Jul 30, 2024お知らせ • Apr 28Nautilus Biotechnology, Inc., Annual General Meeting, Jun 13, 2024Nautilus Biotechnology, Inc., Annual General Meeting, Jun 13, 2024, at 10:00 Pacific Standard Time. Agenda: To elect three Class III directors to hold office until 2027 annual meeting of stockholders and until their respective successors are elected and qualified; to consider and ratify the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2024; and to transact any other business that may properly come before the annual meeting or any adjournments or postponements thereof.お知らせ • Apr 12Nautilus Biotechnology, Inc. to Report Q1, 2024 Results on Apr 30, 2024Nautilus Biotechnology, Inc. announced that they will report Q1, 2024 results Pre-Market on Apr 30, 2024New Risk • Mar 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$134m net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change).Recent Insider Transactions • Mar 11Co-Founder recently bought US$99k worth of stockOn the 7th of March, Sujal Patel bought around 36k shares on-market at roughly US$2.79 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Sujal's only on-market trade for the last 12 months.Major Estimate Revision • Mar 06Consensus revenue estimates decrease by 96%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$5.68m to US$200.0k. EPS estimate increased from -US$0.755 to -US$0.745 per share. Life Sciences industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$4.67 to US$4.25. Share price fell 11% to US$2.61 over the past week.Price Target Changed • Mar 01Price target decreased by 8.9% to US$4.25Down from US$4.67, the current price target is an average from 3 analysts. New target price is 56% above last closing price of US$2.72. Stock is up 24% over the past year. The company is forecast to post a net loss per share of US$0.74 next year compared to a net loss per share of US$0.51 last year.Price Target Changed • Feb 28Price target decreased by 8.3% to US$4.58Down from US$5.00, the current price target is an average from 3 analysts. New target price is 64% above last closing price of US$2.80. Stock is up 30% over the past year. The company is forecast to post a net loss per share of US$0.58 next year compared to a net loss per share of US$0.46 last year.お知らせ • Feb 28Nautilus Biotechnology, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.Nautilus Biotechnology, Inc. has filed a Follow-on Equity Offering in the amount of $125 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering分析記事 • Feb 16We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Feb 08Nautilus Biotechnology, Inc. to Report Q4, 2023 Results on Feb 28, 2024Nautilus Biotechnology, Inc. announced that they will report Q4, 2023 results Pre-Market on Feb 28, 2024Price Target Changed • Jan 06Price target decreased by 12% to US$4.67Down from US$5.33, the current price target is an average from 3 analysts. New target price is 53% above last closing price of US$3.05. Stock is up 71% over the past year. The company is forecast to post a net loss per share of US$0.58 next year compared to a net loss per share of US$0.46 last year.分析記事 • Oct 22Companies Like Nautilus Biotechnology (NASDAQ:NAUT) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...お知らせ • Oct 12Nautilus Biotechnology, Inc. to Report Q3, 2023 Results on Oct 31, 2023Nautilus Biotechnology, Inc. announced that they will report Q3, 2023 results Pre-Market on Oct 31, 2023お知らせ • Jul 12Nautilus Biotechnology, Inc. to Report Q2, 2023 Results on Aug 02, 2023Nautilus Biotechnology, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 02, 2023New Risk • Jun 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 29% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$130m net loss in 2 years). Share price has been volatile over the past 3 months (10% average weekly change).分析記事 • May 25We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Feb 17We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • Jan 27Nautilus Biotechnology, Inc. to Report Q4, 2022 Results on Feb 23, 2023Nautilus Biotechnology, Inc. announced that they will report Q4, 2022 results Pre-Market on Feb 23, 2023Price Target Changed • Nov 16Price target decreased to US$5.00Down from US$7.67, the current price target is an average from 3 analysts. New target price is 149% above last closing price of US$2.01. Stock is down 60% over the past year. The company is forecast to post a net loss per share of US$0.50 next year compared to a net loss per share of US$0.60 last year.Board Change • Nov 16High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Emma Lundberg is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Nov 02Nautilus Biotechnology, Inc. Appoints Karen Akinsanya to Nominating CommitteeNautilus Biotechnology, Inc. announced the appointment of Karen Akinsanya to Nominating Committee, effective immediately. The members of the Nominating Committee are Matthew McIlwain (Chair), Vijay Pande, and Karen Akinsanya.お知らせ • Oct 06Nautilus Biotechnology, Inc. to Report Q3, 2022 Results on Nov 01, 2022Nautilus Biotechnology, Inc. announced that they will report Q3, 2022 results Pre-Market on Nov 01, 2022Recent Insider Transactions • Sep 28Chief People Officer recently bought US$61k worth of stockOn the 23rd of September, Gwen Weld bought around 30k shares on-market at roughly US$2.03 per share. This trade did not impact their existing holding. In the last 3 months, there was an even bigger purchase from another insider worth US$163k. Insiders have collectively bought US$2.8m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Sep 20Insider recently bought US$163k worth of stockOn the 16th of September, Subra Sankar bought around 75k shares on-market at roughly US$2.18 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$2.8m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Aug 10Co-Founder recently bought US$146k worth of stockOn the 8th of August, Sujal Patel bought around 50k shares on-market at roughly US$2.92 per share. This was the largest purchase by an insider in the last 3 months. Sujal has been a buyer over the last 12 months, purchasing a net total of US$1.7m worth in shares.Price Target Changed • Aug 03Price target decreased to US$5.67Down from US$8.00, the current price target is an average from 3 analysts. New target price is 100% above last closing price of US$2.83. Stock is down 62% over the past year. The company is forecast to post a net loss per share of US$0.56 next year compared to a net loss per share of US$0.60 last year.Seeking Alpha • Aug 01Nautilus Biotechnology Q2 2022 Earnings PreviewNautilus Biotechnology (NASDAQ:NAUT) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. The consensus EPS Estimate is -$0.17 (+10.5% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 2 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 1 downward.お知らせ • Jul 14Nautilus Biotechnology, Inc. to Report Q2, 2022 Results on Aug 02, 2022Nautilus Biotechnology, Inc. announced that they will report Q2, 2022 results Pre-Market on Aug 02, 2022Recent Insider Transactions • May 12Co-Founder recently bought US$198k worth of stockOn the 9th of May, Sujal Patel bought around 50k shares on-market at roughly US$3.96 per share. This was the largest purchase by an insider in the last 3 months. Sujal has been a buyer over the last 12 months, purchasing a net total of US$1.6m worth in shares.Major Estimate Revision • May 10Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$2.63m to US$1.44m. EPS estimate unchanged from -US$0.70 per share at last update. Life Sciences industry in the US expected to see average net income growth of 7.2% next year. Consensus price target of US$8.00 unchanged from last update. Share price fell 30% to US$3.31 over the past week.Price Target Changed • Apr 27Price target decreased to US$8.00Down from US$9.33, the current price target is an average from 4 analysts. New target price is 95% above last closing price of US$4.10. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$0.70 next year compared to a net loss per share of US$0.60 last year.Board Change • Apr 27High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Emma Lundberg is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 13Nautilus Biotechnology, Inc. Appoints Gwen Weld as Chief People OfficerNautilus Biotechnology, Inc. announced the appointment of Gwen Weld as Chief People Officer. Gwen Weld brings to Nautilus more than 25 years of senior leadership in human resources, organizational culture, and business strategy. Immediately prior to joining the company, Ms. Weld served as Interim Chief People Officer at Amperity. She previously held the positions of Vice President of Global People and Infrastructure at Isilon Systems for more than six years and General Manager of Human Resources at Microsoft Corporation for nearly twenty years.お知らせ • Apr 08Nautilus Biotechnology, Inc. to Report Q1, 2022 Results on May 03, 2022Nautilus Biotechnology, Inc. announced that they will report Q1, 2022 results Pre-Market on May 03, 2022お知らせ • Apr 01Nautilus Biotechnology, Inc. Appoints Karen Akinsanya to Board of DirectorsNautilus Biotechnology, Inc. announced the appointment of Karen Akinsanya, Ph.D., to its Board of Directors. Dr. Akinsanya brings more than 25 years of experience in drug discovery and development, commercialization, partnerships, and licensing from across academia and pharmaceutical research and development (R&D). In her current role as President of R&D, Therapeutics at Schrödinger, she leads the company’s therapeutics group that leverages Schrödinger's leading physics-based platform for preclinical drug discovery and is responsible for translational research and early development, in addition to business development and collaborations. Prior to joining Schrödinger, Dr. Akinsanya held positions of increasing responsibility during more than a decade at Merck Research Laboratories, as Associate Director of Clinical Pharmacology driving first-in-human studies through late-stage label studies; Executive Director and therapeutic area lead in Discovery Preclinical and Early Development; and AVP of Business Development and Licensing where she managed the search and evaluation of pre-proof of concept therapeutic assets and enabling technologies as well as execution and alliance management of a number of significant licensing and partnering deals.Price Target Changed • Mar 06Price target decreased to US$9.33Down from US$10.33, the current price target is an average from 4 analysts. New target price is 167% above last closing price of US$3.50. Stock is down 76% over the past year. The company is forecast to post a net loss per share of US$0.70 next year compared to a net loss per share of US$0.60 last year.お知らせ • Jan 28Nautilus Biotechnology, Inc. to Report Q4, 2021 Results on Feb 24, 2022Nautilus Biotechnology, Inc. announced that they will report Q4, 2021 results Pre-Market on Feb 24, 2022Seeking Alpha • Jan 17The Take On Nautilus BiotechnologyNautilus Biotechnology, Inc. has lost approximately half its value since its public debut in June 2021. There are no execution issues, just a lack of catalysts until the company achieves the identification of 2,500 proteins in a sample run – expected to occur in early 2022. With an ambitious goal of characterizing the entire proteome – like Illumina with the genome – and significant insider buying, Nautilus merits a deeper dive.Seeking Alpha • Jan 07Nautilus Biotechnology: Recent Selloff Provides A Fantastic Entry PointNautilus operates in the field of Proteomics, a $25 billion market, growing at 12% per year. The company claims to have a solution that could be best in class with designs for a commercial launch near the end of 2023. The market is currently valuing shares at only $2.33 net of cash, making this a high risk, very high reward stock. I have been accumulating shares at current levels.Board Change • Jan 01High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Emma Lundberg is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Recent Insider Transactions • Nov 26CFO & Treasurer recently bought US$69k worth of stockOn the 24th of November, Anna Mowry bought around 15k shares on-market at roughly US$4.58 per share. In the last 3 months, there was an even bigger purchase from another insider worth US$530k. Anna has been a buyer over the last 12 months, purchasing a net total of US$204k worth in shares.Recent Insider Transactions • Nov 23Independent Director recently bought US$530k worth of stockOn the 15th of November, Matthew McIlwain bought around 100k shares on-market at roughly US$5.30 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$1.2m more in shares than they have sold in the last 12 months.Seeking Alpha • Aug 30Nautilus Biotechnology: Tapping The Potential Of The Human ProteomeNautilus Biotechnology seeks to deliver on the untapped potential of the human proteome. The company debuted for public trade on Nasdaq Global Select Market on 6/10/2021. The company started off with gross proceeds of $345 million from the business combination with a SPAC.Recent Insider Transactions • Aug 27Independent Director recently bought US$195k worth of stockOn the 25th of August, Matthew McIlwain bought around 25k shares on-market at roughly US$7.71 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$367k more in shares than they have sold in the last 12 months.Recent Insider Transactions • Aug 17Insider recently bought US$135k worth of stockOn the 12th of August, Anna Mowry bought around 18k shares on-market at roughly US$7.71 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$173k more in shares than they have sold in the last 12 months.お知らせ • Jun 23Nautilus Biotechnology, Inc. announced that it has received $200 million in funding from a group of investorsOn June 22, 2021, Nautilus Biotechnology, Inc. (NasdaqGS:NAUT) closed the transaction. The company received funding from 38 investors pursuant to exemption provided under Regulation D.決済の安定と成長配当データの取得安定した配当: NAUTの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: NAUTの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Nautilus Biotechnology 配当利回り対市場NAUT 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (NAUT)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Life Sciences)0.7%アナリスト予想 (NAUT) (最長3年)n/a注目すべき配当: NAUTは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: NAUTは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: NAUTの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: NAUTが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 05:02終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nautilus Biotechnology, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Matthew SykesGoldman SachsSubhalaxmi NambiGuggenheim Securities, LLCDaniel BrennanTD Cowen
お知らせ • Apr 30Nautilus Biotechnology, Inc., Annual General Meeting, Jun 17, 2026Nautilus Biotechnology, Inc., Annual General Meeting, Jun 17, 2026.
お知らせ • Apr 10Nautilus Biotechnology, Inc. to Report Q1, 2026 Results on Apr 28, 2026Nautilus Biotechnology, Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 28, 2026
New Risk • Apr 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$83m net loss in 3 years).
新しいナラティブ • Mar 05Proteomics Demand And Early Access Services Will Support A Stronger Long Term OpportunityCatalysts About Nautilus Biotechnology Nautilus Biotechnology is developing a proteomics platform built around its Voyager instrument and Iterative Mapping technology to measure proteins and proteoforms at single molecule resolution for research and drug discovery customers. What are the underlying business or industry changes driving this perspective?
お知らせ • Feb 25Nautilus Biotechnology, Inc. Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, At US HUPO 2026Nautilus Biotechnology, Inc. debuted the Voyager Platform, which is designed to power the Iterative Mapping of up to 10 billion intact proteins and proteoforms simultaneously in a single run. The Voyager Platform was unveiled during the US HUPO 2026 conference in St. Louis, highlighting its ability to identify and quantify intact protein molecules with machine-learning powered analysis - all on an integrated platform with a user-friendly touchscreen interface and benchtop design that requires no special lab facility requirements. The Voyager Platform is the result of Nautilus' unique cross-disciplinary approach to protein analysis, combining integrated reagents, fluidics, imaging, ultra-dense nano-array flow cells, and machine learning-powered algorithms, to enable Iterative Mapping and deliver on the full potential of proteomics. The company launched its Iterative Mapping Early Access Program in January 2026 to provide scientists with an initial opportunity to use Nautilus' novel single-molecule proteomic analysis method and platform ahead of commercial availability. The program is currently accepting project proposals and is offered first as a fee-for-service through Nautilus Proteomics Analysis Services, followed by a limited number of Voyager instrument placements in advance of full commercial launch expected in late 2026. The program's initial offering is the Nautilus Tau Proteoforms assay, which enables quantification of up to 768 full-length tau proteoform groups that are not accessible with standard proteomics methods. Results from Nautilus' ongoing collaboration with the Buck Institute have established the instrument's qualification and readiness for broader research applications. Joint research results between Nautilus and the Buck Institute have provided insights into novel tau biology and are now being presented at scientific conferences. In addition to the platform showcase, Nautilus will present data across multiple sessions at US HUPO, including an oral presentation on advancing proteomics through Iterative Mapping, posters detailing tau proteoform analysis in Alzheimer's disease and large-scale proteoform detection capabilities, and a sponsored lunch seminars. On February 24, February 24, 2026, Nautilus' Vice President of Scientific Engagement, Sheri Wilcox, Ph.D., and Birgit Schilling, Ph.D., Associate Professor and Director of the Mass Spectrometry Core at the Buck Institute for Research on Aging, will showcase how Iterative Mapping is transforming proteomics and enabling new insights into the role of tau biology in neurodegeneration and aging.
お知らせ • Feb 05Nautilus Biotechnology, Inc. to Report Q4, 2025 Results on Feb 26, 2026Nautilus Biotechnology, Inc. announced that they will report Q4, 2025 results Pre-Market on Feb 26, 2026
お知らせ • Jan 08Nautilus Biotechnology, Inc. Announces the Launch of an Early Access ProgramNautilus Biotechnology, Inc. announced the launch of an Early Access Program for its novel proteomics platform, with a tau proteoforms assay as its first offering. The program makes Nautilus' Iterative Mapping approach to measuring proteins and their variants available to an exclusive group of researchers. Nautilus' IterativeMapping method enables single-molecule analysis of proteins and proteoforms and is designed to achieve comprehensive proteome coverage and detail at scale. The method empowers researchers to precisely map combinatorial patterns of post-translational modifications on individual proteins and study how those patterns evolve over the course of diseases such as Alzheimer's and other neurodegenerative disorders. Participants will receive support from Nautilus for guidance on data interpretation, quantification, and analysis, supporting rapid adoption and the generation of actionable biological insights. The tau proteoforms assay demonstrates the strong performance and accessibility of the Nautilus Platform. A Nautilus preprint debuting the assay details the platform's capabilities in analyzing Alzheimer's disease brain samples, providing initial validation of its accuracy, sensitivity, dynamic range, and reproducibility for interacting billions of single-protein molecules at scale. Successful adoption by first-time users at the Buck Institute reinforces the platform's accessibility and commercial readiness for research use. In addition to standard tau assays for Alzheimer's and neurodegenerative research, the Early Access Program offers exclusive development partnerships to support the creation of custom assays tailored to specific research applications.
お知らせ • Nov 05Nautilus Biotechnology Reports Successful Installation and Testing of Its First Field Evaluation Unit At the Buck Institute for Research on AgingNautilus Biotechnology, Inc. and the Buck Institute for Research on Aging announced the successful installation and testing of Nautilus' first external field evaluation unit. Using the instrument for more than 6 months, researchers generated highly reproducible data from neurodegenerative disease samples prepared and acquired at the Buck Institute in the San Francisco Bay Area, CA. The operation of Nautilus' first instrument deployed at an external site marks a critical milestone in providing independent research labs with direct access to the company's single-molecule proteomics platform, as well as in its acceleration of broader research and development efforts to investigate severe conditions such as Alzheimer's disease. Birgit Schilling and Lisa Ellerby, were the first to install, pilot, and utilize the Nautilus platform on their grounds - it is a testament to rigorous approach to conducting and bringing high-caliber science into labs everywhere. The unit employs Nautilus' Iterative Mapping approach and proprietary tau proteoform assay developed to quantify 7768 proteoform groups, enabling the Buck Institute to apply to their samples high-resolution analysis of the protein modifications that most strongly influence disease progression. Their joint efforts demonstrated that the tau assay generates highly reproducible end-to-end platform data across sites and users and established the instrument's qualification and readiness for broader research applications.
お知らせ • Oct 07Nautilus Biotechnology, Inc. to Report Q3, 2025 Results on Oct 28, 2025Nautilus Biotechnology, Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Oct 28, 2025
Recent Insider Transactions • Sep 11Co-Founder recently bought US$136k worth of stockOn the 8th of September, Sujal Patel bought around 200k shares on-market at roughly US$0.68 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Sujal has been a buyer over the last 12 months, purchasing a net total of US$159k worth in shares.
Price Target Changed • Jul 29Price target increased by 33% to US$2.50Up from US$1.88, the current price target is provided by 1 analyst. New target price is 235% above last closing price of US$0.75. Stock is down 72% over the past year. The company is forecast to post a net loss per share of US$0.60 next year compared to a net loss per share of US$0.56 last year.
お知らせ • Jul 15Nautilus Biotechnology, Inc. to Report Q2, 2025 Results on Jul 31, 2025Nautilus Biotechnology, Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 31, 2025
Price Target Changed • Jun 04Price target increased by 16% to US$2.17Up from US$1.88, the current price target is an average from 3 analysts. New target price is 180% above last closing price of US$0.77. Stock is down 70% over the past year. The company is forecast to post a net loss per share of US$0.59 next year compared to a net loss per share of US$0.56 last year.
お知らせ • May 03Nautilus Biotechnology Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketOn May 1st, 2025, Nautilus Biotechnology, Inc. received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between March 19, 2025, through April 30, 2025, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until October 28, 2025 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). The letter has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on Nasdaq, subject to the Company’s compliance with the other listing requirements of Nasdaq. In order to regain compliance with Nasdaq’s minimum bid price requirement, shares of the Company’s common stock must maintain a closing bid price of at least $1.00 for a minimum of ten consecutive business days during the Compliance Period, unless the Staff exercises its discretion to extend this ten day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). In the event the Company does not regain compliance by the end of the Compliance Period, the Company may be eligible for an additional 180 calendar days to regain compliance (the “Second Compliance Period”) pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(i) by transferring to the Nasdaq Capital Market. To qualify for the Second Compliance Period, the Company would need to submit a transfer application and pay an application fee. In addition, the Company would be required to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for Nasdaq, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the Second Compliance Period by effecting a reverse stock split, if necessary. However, if it appears to Nasdaq that the Company will be unable to cure the deficiency, or if the Company is not otherwise eligible for the additional cure period, Nasdaq will provide notice that the Company’s shares of common stock will be subject to delisting. There can be no assurance that the Company will be eligible for the Second Compliance Period, if applicable, or that the Staff would grant the Company’s request for continued listing subsequent to any delisting notification. The Company intends to actively monitor the closing bid price of its shares of common stock during the Compliance Period and may, if appropriate, evaluate available options to resolve the deficiency and regain compliance with the minimum bid price requirement. While the Company is exercising diligent efforts to maintain the listing of its common stock on the Nasdaq Global Select Market, there can be no assurance that the Company will be able to regain or maintain compliance with the minimum bid price requirement or any other Nasdaq listing standard.
お知らせ • May 01Nautilus Biotechnology, Inc., Annual General Meeting, Jun 20, 2025Nautilus Biotechnology, Inc., Annual General Meeting, Jun 20, 2025.
Price Target Changed • Apr 29Price target increased by 16% to US$2.17Up from US$1.88, the current price target is an average from 3 analysts. New target price is 195% above last closing price of US$0.73. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$0.65 next year compared to a net loss per share of US$0.56 last year.
お知らせ • Apr 16Nautilus Biotechnology, Inc. to Report Q1, 2025 Results on Apr 29, 2025Nautilus Biotechnology, Inc. announced that they will report Q1, 2025 results Pre-Market on Apr 29, 2025
New Risk • Apr 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$94.7m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 8.2% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$99m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$94.7m market cap).
Seeking Alpha • Feb 28Nautilus: Trading Below An Albeit Lower Net Cash FigureSummary Nautilus Biotechnology, Inc. faces reflexivity risks and macroeconomic challenges, but its commercial plan starts next year with substantial cash reserves. Trading below cash value, Nautilus' patents and bio-informatics platform are not being given too much credit by markets. Although, they seem to expect that company to be minimally viable once they have an additional $30 million of cash, which still may not be enough depending on commercial costs. The company aims for commercialization by late 2026, with anticipated ASPs above $1 million, but that doesn't sound like it will be enough, and we'll need to see commercial outcomes. NAUT stock is probably still going to be subject to reflexivity risks for a while, so we stay on the sidelines while costs of capital remain stubbornly higher. Read the full article on Seeking Alpha
New Risk • Feb 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 7.7% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$99m net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change).
Price Target Changed • Feb 28Price target increased by 12% to US$4.00Up from US$3.56, the current price target is an average from 3 analysts. New target price is 208% above last closing price of US$1.30. Stock is down 52% over the past year. The company is forecast to post a net loss per share of US$0.67 next year compared to a net loss per share of US$0.56 last year.
お知らせ • Feb 06Nautilus Biotechnology, Inc. to Report Q4, 2024 Results on Feb 27, 2025Nautilus Biotechnology, Inc. announced that they will report Q4, 2024 results Pre-Market on Feb 27, 2025
New Risk • Dec 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 11% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$107m net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change).
Price Target Changed • Oct 30Price target decreased by 14% to US$3.56Down from US$4.13, the current price target is an average from 4 analysts. New target price is 34% above last closing price of US$2.65. Stock is up 3.5% over the past year. The company is forecast to post a net loss per share of US$0.64 next year compared to a net loss per share of US$0.51 last year.
お知らせ • Oct 08Nautilus Biotechnology, Inc. to Report Q3, 2024 Results on Oct 29, 2024Nautilus Biotechnology, Inc. announced that they will report Q3, 2024 results Pre-Market on Oct 29, 2024
Recent Insider Transactions Derivative • Sep 19Senior Vice President of Operations notifies of intention to sell stockMary Godwin intends to sell 35k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of September. If the sale is conducted around the recent share price of US$2.85, it would amount to US$100k. As of today, Mary currently holds no shares directly (This sale likely refers to shares that have not yet been received). Company insiders have collectively bought US$57k more than they sold, via options and on-market transactions, in the last 12 months.
お知らせ • Sep 17Nautilus Biotechnology, Inc. Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing OfficerNautilus Biotechnology, Inc. announced the appointment of Kentaro (Ken) Suzuki as Chief Marketing Officer. Mr. Suzuki joins Nautilus after 25 years in product and marketing leadership roles at Agilent Technologies, most recently serving as Vice President and General Manager of Agilent’s Mass Spectrometry division. He has held numerous leadership positions at Agilent, including in the Strategic Program Office and Certified Pre-Owned Instruments, CrossLab Services and Support, and Spectroscopy. Mr. Suzuki’s track record in the life sciences and technology sector spans nearly three decades of innovation across marketing, product, finance, and research and development. Previously, he held roles in application and sales at Takeda Pharmaceuticals in Tokyo, Japan, and in finance at Hewlett-Packard (HP) before contributing to the founding of Agilent. Mr. Suzuki received his M.B.A. from the Haas School of Business at the University of California, Berkeley, and his B.S. in Biological Engineering from Cornell University. He will be based in Nautilus’ research and development headquarters in the San Francisco Bay Area.
分析記事 • Jul 27We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
お知らせ • Jul 10Nautilus Biotechnology, Inc. to Report Q2, 2024 Results on Jul 30, 2024Nautilus Biotechnology, Inc. announced that they will report Q2, 2024 results Pre-Market on Jul 30, 2024
お知らせ • Apr 28Nautilus Biotechnology, Inc., Annual General Meeting, Jun 13, 2024Nautilus Biotechnology, Inc., Annual General Meeting, Jun 13, 2024, at 10:00 Pacific Standard Time. Agenda: To elect three Class III directors to hold office until 2027 annual meeting of stockholders and until their respective successors are elected and qualified; to consider and ratify the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2024; and to transact any other business that may properly come before the annual meeting or any adjournments or postponements thereof.
お知らせ • Apr 12Nautilus Biotechnology, Inc. to Report Q1, 2024 Results on Apr 30, 2024Nautilus Biotechnology, Inc. announced that they will report Q1, 2024 results Pre-Market on Apr 30, 2024
New Risk • Mar 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$134m net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change).
Recent Insider Transactions • Mar 11Co-Founder recently bought US$99k worth of stockOn the 7th of March, Sujal Patel bought around 36k shares on-market at roughly US$2.79 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Sujal's only on-market trade for the last 12 months.
Major Estimate Revision • Mar 06Consensus revenue estimates decrease by 96%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$5.68m to US$200.0k. EPS estimate increased from -US$0.755 to -US$0.745 per share. Life Sciences industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$4.67 to US$4.25. Share price fell 11% to US$2.61 over the past week.
Price Target Changed • Mar 01Price target decreased by 8.9% to US$4.25Down from US$4.67, the current price target is an average from 3 analysts. New target price is 56% above last closing price of US$2.72. Stock is up 24% over the past year. The company is forecast to post a net loss per share of US$0.74 next year compared to a net loss per share of US$0.51 last year.
Price Target Changed • Feb 28Price target decreased by 8.3% to US$4.58Down from US$5.00, the current price target is an average from 3 analysts. New target price is 64% above last closing price of US$2.80. Stock is up 30% over the past year. The company is forecast to post a net loss per share of US$0.58 next year compared to a net loss per share of US$0.46 last year.
お知らせ • Feb 28Nautilus Biotechnology, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.Nautilus Biotechnology, Inc. has filed a Follow-on Equity Offering in the amount of $125 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
分析記事 • Feb 16We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Feb 08Nautilus Biotechnology, Inc. to Report Q4, 2023 Results on Feb 28, 2024Nautilus Biotechnology, Inc. announced that they will report Q4, 2023 results Pre-Market on Feb 28, 2024
Price Target Changed • Jan 06Price target decreased by 12% to US$4.67Down from US$5.33, the current price target is an average from 3 analysts. New target price is 53% above last closing price of US$3.05. Stock is up 71% over the past year. The company is forecast to post a net loss per share of US$0.58 next year compared to a net loss per share of US$0.46 last year.
分析記事 • Oct 22Companies Like Nautilus Biotechnology (NASDAQ:NAUT) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
お知らせ • Oct 12Nautilus Biotechnology, Inc. to Report Q3, 2023 Results on Oct 31, 2023Nautilus Biotechnology, Inc. announced that they will report Q3, 2023 results Pre-Market on Oct 31, 2023
お知らせ • Jul 12Nautilus Biotechnology, Inc. to Report Q2, 2023 Results on Aug 02, 2023Nautilus Biotechnology, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 02, 2023
New Risk • Jun 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 29% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$130m net loss in 2 years). Share price has been volatile over the past 3 months (10% average weekly change).
分析記事 • May 25We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Feb 17We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • Jan 27Nautilus Biotechnology, Inc. to Report Q4, 2022 Results on Feb 23, 2023Nautilus Biotechnology, Inc. announced that they will report Q4, 2022 results Pre-Market on Feb 23, 2023
Price Target Changed • Nov 16Price target decreased to US$5.00Down from US$7.67, the current price target is an average from 3 analysts. New target price is 149% above last closing price of US$2.01. Stock is down 60% over the past year. The company is forecast to post a net loss per share of US$0.50 next year compared to a net loss per share of US$0.60 last year.
Board Change • Nov 16High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Emma Lundberg is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Nov 02Nautilus Biotechnology, Inc. Appoints Karen Akinsanya to Nominating CommitteeNautilus Biotechnology, Inc. announced the appointment of Karen Akinsanya to Nominating Committee, effective immediately. The members of the Nominating Committee are Matthew McIlwain (Chair), Vijay Pande, and Karen Akinsanya.
お知らせ • Oct 06Nautilus Biotechnology, Inc. to Report Q3, 2022 Results on Nov 01, 2022Nautilus Biotechnology, Inc. announced that they will report Q3, 2022 results Pre-Market on Nov 01, 2022
Recent Insider Transactions • Sep 28Chief People Officer recently bought US$61k worth of stockOn the 23rd of September, Gwen Weld bought around 30k shares on-market at roughly US$2.03 per share. This trade did not impact their existing holding. In the last 3 months, there was an even bigger purchase from another insider worth US$163k. Insiders have collectively bought US$2.8m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Sep 20Insider recently bought US$163k worth of stockOn the 16th of September, Subra Sankar bought around 75k shares on-market at roughly US$2.18 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$2.8m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Aug 10Co-Founder recently bought US$146k worth of stockOn the 8th of August, Sujal Patel bought around 50k shares on-market at roughly US$2.92 per share. This was the largest purchase by an insider in the last 3 months. Sujal has been a buyer over the last 12 months, purchasing a net total of US$1.7m worth in shares.
Price Target Changed • Aug 03Price target decreased to US$5.67Down from US$8.00, the current price target is an average from 3 analysts. New target price is 100% above last closing price of US$2.83. Stock is down 62% over the past year. The company is forecast to post a net loss per share of US$0.56 next year compared to a net loss per share of US$0.60 last year.
Seeking Alpha • Aug 01Nautilus Biotechnology Q2 2022 Earnings PreviewNautilus Biotechnology (NASDAQ:NAUT) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. The consensus EPS Estimate is -$0.17 (+10.5% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 2 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 1 downward.
お知らせ • Jul 14Nautilus Biotechnology, Inc. to Report Q2, 2022 Results on Aug 02, 2022Nautilus Biotechnology, Inc. announced that they will report Q2, 2022 results Pre-Market on Aug 02, 2022
Recent Insider Transactions • May 12Co-Founder recently bought US$198k worth of stockOn the 9th of May, Sujal Patel bought around 50k shares on-market at roughly US$3.96 per share. This was the largest purchase by an insider in the last 3 months. Sujal has been a buyer over the last 12 months, purchasing a net total of US$1.6m worth in shares.
Major Estimate Revision • May 10Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$2.63m to US$1.44m. EPS estimate unchanged from -US$0.70 per share at last update. Life Sciences industry in the US expected to see average net income growth of 7.2% next year. Consensus price target of US$8.00 unchanged from last update. Share price fell 30% to US$3.31 over the past week.
Price Target Changed • Apr 27Price target decreased to US$8.00Down from US$9.33, the current price target is an average from 4 analysts. New target price is 95% above last closing price of US$4.10. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$0.70 next year compared to a net loss per share of US$0.60 last year.
Board Change • Apr 27High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Emma Lundberg is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 13Nautilus Biotechnology, Inc. Appoints Gwen Weld as Chief People OfficerNautilus Biotechnology, Inc. announced the appointment of Gwen Weld as Chief People Officer. Gwen Weld brings to Nautilus more than 25 years of senior leadership in human resources, organizational culture, and business strategy. Immediately prior to joining the company, Ms. Weld served as Interim Chief People Officer at Amperity. She previously held the positions of Vice President of Global People and Infrastructure at Isilon Systems for more than six years and General Manager of Human Resources at Microsoft Corporation for nearly twenty years.
お知らせ • Apr 08Nautilus Biotechnology, Inc. to Report Q1, 2022 Results on May 03, 2022Nautilus Biotechnology, Inc. announced that they will report Q1, 2022 results Pre-Market on May 03, 2022
お知らせ • Apr 01Nautilus Biotechnology, Inc. Appoints Karen Akinsanya to Board of DirectorsNautilus Biotechnology, Inc. announced the appointment of Karen Akinsanya, Ph.D., to its Board of Directors. Dr. Akinsanya brings more than 25 years of experience in drug discovery and development, commercialization, partnerships, and licensing from across academia and pharmaceutical research and development (R&D). In her current role as President of R&D, Therapeutics at Schrödinger, she leads the company’s therapeutics group that leverages Schrödinger's leading physics-based platform for preclinical drug discovery and is responsible for translational research and early development, in addition to business development and collaborations. Prior to joining Schrödinger, Dr. Akinsanya held positions of increasing responsibility during more than a decade at Merck Research Laboratories, as Associate Director of Clinical Pharmacology driving first-in-human studies through late-stage label studies; Executive Director and therapeutic area lead in Discovery Preclinical and Early Development; and AVP of Business Development and Licensing where she managed the search and evaluation of pre-proof of concept therapeutic assets and enabling technologies as well as execution and alliance management of a number of significant licensing and partnering deals.
Price Target Changed • Mar 06Price target decreased to US$9.33Down from US$10.33, the current price target is an average from 4 analysts. New target price is 167% above last closing price of US$3.50. Stock is down 76% over the past year. The company is forecast to post a net loss per share of US$0.70 next year compared to a net loss per share of US$0.60 last year.
お知らせ • Jan 28Nautilus Biotechnology, Inc. to Report Q4, 2021 Results on Feb 24, 2022Nautilus Biotechnology, Inc. announced that they will report Q4, 2021 results Pre-Market on Feb 24, 2022
Seeking Alpha • Jan 17The Take On Nautilus BiotechnologyNautilus Biotechnology, Inc. has lost approximately half its value since its public debut in June 2021. There are no execution issues, just a lack of catalysts until the company achieves the identification of 2,500 proteins in a sample run – expected to occur in early 2022. With an ambitious goal of characterizing the entire proteome – like Illumina with the genome – and significant insider buying, Nautilus merits a deeper dive.
Seeking Alpha • Jan 07Nautilus Biotechnology: Recent Selloff Provides A Fantastic Entry PointNautilus operates in the field of Proteomics, a $25 billion market, growing at 12% per year. The company claims to have a solution that could be best in class with designs for a commercial launch near the end of 2023. The market is currently valuing shares at only $2.33 net of cash, making this a high risk, very high reward stock. I have been accumulating shares at current levels.
Board Change • Jan 01High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Emma Lundberg is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Recent Insider Transactions • Nov 26CFO & Treasurer recently bought US$69k worth of stockOn the 24th of November, Anna Mowry bought around 15k shares on-market at roughly US$4.58 per share. In the last 3 months, there was an even bigger purchase from another insider worth US$530k. Anna has been a buyer over the last 12 months, purchasing a net total of US$204k worth in shares.
Recent Insider Transactions • Nov 23Independent Director recently bought US$530k worth of stockOn the 15th of November, Matthew McIlwain bought around 100k shares on-market at roughly US$5.30 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$1.2m more in shares than they have sold in the last 12 months.
Seeking Alpha • Aug 30Nautilus Biotechnology: Tapping The Potential Of The Human ProteomeNautilus Biotechnology seeks to deliver on the untapped potential of the human proteome. The company debuted for public trade on Nasdaq Global Select Market on 6/10/2021. The company started off with gross proceeds of $345 million from the business combination with a SPAC.
Recent Insider Transactions • Aug 27Independent Director recently bought US$195k worth of stockOn the 25th of August, Matthew McIlwain bought around 25k shares on-market at roughly US$7.71 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$367k more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Aug 17Insider recently bought US$135k worth of stockOn the 12th of August, Anna Mowry bought around 18k shares on-market at roughly US$7.71 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$173k more in shares than they have sold in the last 12 months.
お知らせ • Jun 23Nautilus Biotechnology, Inc. announced that it has received $200 million in funding from a group of investorsOn June 22, 2021, Nautilus Biotechnology, Inc. (NasdaqGS:NAUT) closed the transaction. The company received funding from 38 investors pursuant to exemption provided under Regulation D.
